The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of June 2023, we identify the following current VC trends in the US-Biotech sector:
- In 2023, overall Biotech funding in the USA has reached USD 9,562m
- Compared to June 2022 the financing volume decreased twofold (20,106m vs. 9,562m)
- Oncology dominates as the top indication
- Upstream Bio has the highest transaction Volume of USD 200m in June, followed by Alkeus Pharmaceuticals USD 150m and Bitterroot Bio USD 145m
- ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by Alexandria Venture Investments (USA) and Google Ventures (USA)
- The top 5 deals exceed USD 190m each, largest transaction amounted to USD 401m in ElevateBio
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 08/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 08/2023”. The Monitor is a monthly published overview of venture capital trends in the European
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 07/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 07/2023”. The Monitor is a monthly published overview of venture capital trends in the European
FCF Biotech Venture Capital Monitor – USA 06/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 06/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 06/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2023”. The Monitor is a monthly published overview of venture capital trends in the European
FCF Biotech Venture Capital Monitor – USA 05/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 05/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
